Chinook Therapeutics (KDNY) Stock Forecast, Price Target & Predictions
KDNY Stock Forecast
Chinook Therapeutics stock forecast is as follows: an average price target of $30.00 (represents a -25.72% downside from KDNY’s last price of $40.39) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
KDNY Price Target
The average price target for Chinook Therapeutics (KDNY) is $30.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $30.00 to $30.00. This represents a potential -25.72% downside from KDNY's last price of $40.39.
KDNY Analyst Ratings
According to 4 Wall Street analysts, Chinook Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for KDNY stock is 0 'Strong Buy' (0.00%), 3 'Buy' (75.00%), 1 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Chinook Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 05, 2022 | - | Wells Fargo | $30.00 | $23.56 | 27.33% | -25.72% |
The latest Chinook Therapeutics stock forecast, released on Dec 05, 2022 by Wells Fargo company, set a price target of $30.00, which represents a 27.33% increase from the stock price at the time of the forecast ($23.56), and a -25.72% decrease from KDNY last price ($40.39).
Chinook Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $40.39 | $40.39 | $40.39 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Chinook Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Chinook Therapeutics's last price of $40.39. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 14, 2023 | BTIG | - | Buy | Initialise |
| Jun 14, 2023 | JonesTrading | - | Buy | Initialise |
| Jun 12, 2023 | Guggenheim | - | Neutral | Downgrade |
| Dec 05, 2022 | Wells Fargo | - | Overweight | Initialise |
Chinook Therapeutics's last stock rating was published by BTIG on Jun 14, 2023. The company Initialise its KDNY rating from "null" to "Buy".
Chinook Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $2.15 | $33.86 | 1474.88% | Buy |
| PLRX | Pliant Therapeutics | $14.49 | $39.71 | 174.05% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.81 | $38.80 | 161.99% | Buy |
| GPCR | Structure Therapeutics | $39.74 | $92.40 | 132.51% | Buy |
| KALV | KalVista Pharmaceuticals | $11.63 | $26.00 | 123.56% | Buy |
| SWTX | SpringWorks Therapeutics | $30.94 | $67.33 | 117.61% | Buy |
| VRDN | Viridian Therapeutics | $22.84 | $37.83 | 65.63% | Buy |
| ASND | Ascendis Pharma | $125.77 | $190.21 | 51.24% | Buy |
| KURA | Kura Oncology | $17.81 | $26.00 | 45.99% | Buy |
| DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
| CRNX | Crinetics Pharmaceuticals | $56.82 | $70.14 | 23.44% | Buy |
| RNA | Avidity Biosciences | $44.82 | $54.50 | 21.60% | Buy |
| NUVL | Nuvalent | $89.53 | $107.83 | 20.44% | Buy |
| TVTX | Travere Therapeutics | $18.10 | $21.38 | 18.12% | Buy |
| PCVX | Vaxcyte | $106.49 | $124.14 | 16.57% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $55.87 | $58.57 | 4.83% | Buy |
| ACLX | Arcellx | $86.44 | $71.57 | -17.20% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |
| KDNY | Chinook Therapeutics | $40.39 | $30.00 | -25.72% | Buy |
KDNY Forecast FAQ
Is Chinook Therapeutics a good buy?
Yes, according to 4 Wall Street analysts, Chinook Therapeutics (KDNY) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 75.00% of KDNY's total ratings.
What is KDNY's price target?
Chinook Therapeutics (KDNY) average price target is $30 with a range of $30 to $30, implying a -25.72% from its last price of $40.39. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Chinook Therapeutics stock go up soon?
According to Wall Street analysts' prediction for KDNY stock, the company can go down by -25.72% (from the last price of $40.39 to the average price target of $30), down by -25.72% based on the highest stock price target, and down by -25.72% based on the lowest stock price target.
Can Chinook Therapeutics stock reach $60?
KDNY's average twelve months analyst stock price target of $30 does not support the claim that Chinook Therapeutics can reach $60 in the near future.